Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Category: Uncategorized

Nafarelin

Our opinion on this compoundEstablished workhorse

40/100

Mature FDA-approved GnRH superagonist with intranasal uniqueness but limited modern research frontier value

Look, nafarelin is a genuinely interesting piece of peptide chemistry history, but interesting history and compelling research target in 2026 are two different things. The D-3-(2-naphthyl)alanine substitution at position 6 was clever when the Syntex peptide chemistry group built it in the early 1980s: it solved the aminopeptidase stability problem and pushed receptor affinity approximately 200-fold above native GnRH. That work directly informed the broader structure-activity program that produced the entire GnRH superagonist class. We appreciate the chemistry. It was good chemistry.

The problem is that the mechanism is now completely characterized, the clinical picture is mature, and the class itself is well-populated with alternatives. GnRH receptor desensitization through continuous agonism is textbook pharmacology. There’s no ambiguity about what’s happening: continuous gonadotrope stimulation downregulates receptor expression within two to four weeks and drives LH and FSH output to castrate or prepubertal levels. The tissue-level estradiol and testosterone suppression that follows is predictable and well-documented. That’s clean pharmacology, but it’s not a research frontier by any definition the rubric is trying to reward.

Within the class, nafarelinss one real claim to differentiation is the intranasal route. Its the only GnRH agonist delivered exclusively by nasal spray in clinical practice, and there’s a small but legitimate use-case for non-injectable pituitary suppression in IVF protocols and for patient preference in CPP management. But that’s an operational characteristic, not a mechanistic edge. For researchers working on GnRH pulse frequency pharmacology, hypothalamic-pituitary axis signaling, or receptor internalization kinetics, leuprolide acetate has a far denser research footprint and is the workhorse used in most model designs. For pediatric CPP, histrelin’s implant pharmacokinetics make it the more tractable study tool.

What nafarelin does have going for it is evidence quality. Approved 1990, decades of head-to-head comparisons against goserelin and leuprolide in endometriosis and ART, a well-characterized safety profile including the bone mineral density time-course data from the 6-month endometriosis trials. The 2.8 percent intranasal bioavailability is precisely characterized, which is actually useful if youre specifically studying intranasal peptide delivery. That evidence base is real. But it cuts both ways: an approved drug with thoroughly worked-out pharmacology in a crowded class mostly means there isn’t much left to discover.

Honestly, the places nafarelin still earns bench attention are specific and narrow. If you’re building a GnRH receptor desensitization model and need a non-injectable agonist with known kinetics, it works. If you’re doing comparative intranasal peptide absorption work, the nafarelin pharmacokinetic dataset is a legitimate reference. Beyond that, we think investigator time is better spent on compounds where the mechanism, the indication space, or the receptor pharmacology is still actively being defined. Nafarelin is a solved problem. Good for it.

Novelty

18

Mechanism promise

20

In-category differentiation

38

Evidence quality

73

Translational signal

70

Research bench value

38

Rationale Nafarelin is a 1990-approved GnRH superagonist in a fully saturated drug class with completely characterized mechanism and well-established clinical profile; the intranasal delivery route is unique within the class but confers no mechanistic novelty, and leuprolide dominates research use, leaving investigators little uncharted territory to work with.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Gonadotropin-releasing hormone superagonist decapeptide with pituitary GnRH receptor desensitization activity

A synthetic decapeptide analog of gonadotropin-releasing hormone bearing a D-3-(2-naphthyl)alanine substitution at position 6, developed at Syntex Research as an intranasal GnRH superagonist approximately 200-fold more potent than native GnRH, FDA-approved for endometriosis and central precocious puberty through sustained pituitary gonadotrope desensitization and consequent suppression of gonadal steroidogenesis.

Abstract

Nafarelin (5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-3-(2-naphthyl)-D-alanyl-L-leucyl-L-arginyl-L-prolyl-glycinamide; CAS 76932-56-4 free base; molecular formula C66H83N17O13; molecular weight 1322.47) is a synthetic decapeptide superagonist analog of gonadotropin-releasing hormone (GnRH) that achieves approximately 200-fold greater receptor affinity than the native decapeptide through substitution of the bulky hydrophobic D-3-(2-naphthyl)alanine residue at position 6, conferring both enhanced receptor binding and resistance to aminopeptidase degradation. Developed at Syntex Research in the early 1980s and approved by the United States Food and Drug Administration on February 13, 1990 as Synarel (nafarelin acetate nasal solution), the compound was the first new pharmacotherapy for endometriosis to enter the US market in 14 years and remains the only GnRH agonist administered exclusively by intranasal spray in clinical practice. The mechanism of action follows the class pharmacology of GnRH superagonists: acute administration produces an initial stimulatory flare of luteinizing hormone and follicle-stimulating hormone release from anterior pituitary gonadotropes, followed within 2 to 4 weeks of continuous twice-daily intranasal dosing by profound receptor desensitization, downregulation of GnRH receptor expression, and consequent suppression of gonadotropin secretion to castrate or prepubertal levels, with parallel suppression of ovarian estradiol to postmenopausal concentrations (less than 20 pg/mL) or testicular testosterone to castrate concentrations. The resulting pharmacological hypoestrogenism or hypogonadism underlies the established clinical applications: management of pelvic pain and reduction in size and number of endometriotic implants in women 18 years and older (400 micrograms daily by intranasal spray for 6 months), and suppression of pubertal development in children with central precocious puberty (1600 micrograms daily by intranasal spray). An additional established clinical application is pituitary downregulation prior to controlled ovarian hyperstimulation in assisted reproductive technology cycles, where nafarelin produces pituitary suppression equivalent to leuprolide and triptorelin with the operational advantage of non-injectable self-administration. Pharmacokinetics after intranasal administration are characterized by rapid absorption through the nasal mucosa (peak plasma concentration at 10 to 40 minutes), low absolute bioavailability of approximately 2.8 percent (range 1.2 to 5.6 percent), plasma protein binding of 80 percent, metabolism by tissue peptidases rather than hepatic cytochrome P450 enzymes, and an elimination half-life of 2.5 to 3.0 hours by the intranasal route. The compound is well tolerated within the constraints of its mechanism: the principal adverse events are the predictable consequences of pharmacological hypoestrogenism (hot flashes in up to 90 percent of adult patients, decreased bone mineral density of 3 to 6 percent over 6 months of treatment with partial but incomplete reversal on cessation, vaginal dryness, decreased libido, emotional lability) and local nasal irritation (approximately 10 percent). The bone mineral density concern limits treatment duration to 6 months in the registered endometriosis indication without add-back therapy. This monograph reviews the chemistry, synthesis, and structure-activity relationships of nafarelin; the GnRH receptor pharmacology and desensitization mechanism; comprehensive pharmacokinetics; the clinical evidence base across endometriosis, central precocious puberty, assisted reproduction, uterine leiomyomas, and investigational applications; sourcing and quality verification; reconstitution and handling; stack interactions; adverse-event profile; and a comparative assessment of five GnRH agonist alternatives against nafarelin on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1396Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 10, 2026
Pemvidutide

Our opinion on this compoundNovel frontier

70/100

Balanced GLP-1/GCGR dual agonist with exceptional Phase 2b MASH biopsy data and FDA Breakthrough Therapy Designation

Look, the GLP-1 receptor agonist story has been told. Semaglutide changed metabolic medicine. Tirzepatide added GIP and extended the effect. What pemvidutide does is point the second receptor somewhere different: straight at the liver. The glucagon receptor axis drives hepatic fatty acid beta-oxidation and suppresses de novo lipogenesis directly, producing a pharmacology that is mechanistically suited to MASH in a way that a GLP-1-only agent isn’t. The 1:1 GLP-1R/GCGR co-agonism ratio is deliberate: glucagon raises glucose, GLP-1 counters it, and the net glycemic result is approximately neutral at therapeutic doses. That’s an elegant design choice that lets the compound go after the liver without glycemic misfires in a metabolically fragile population.

The EuPort glycolipid conjugation is worth noting on its own terms. The 18-carbon diacid alkyl chain creates near-quantitative but transient albumin binding that extends plasma half-life to weekly dosing without a titration requirement. That’s a real formulation engineering advance, and it’s structurally distinct from the fatty diacid chemistry semaglutide uses, making it an interesting probe for half-life extension strategy comparisons as well.

The clinical signal is what puts this compound on the priority list. In the Phase 1b/2a MASLD study (Harrison et al. 2025), 1.8 mg weekly produced a 68.5% relative reduction in liver fat by MRI-PDFF at 12 weeks, extending to 75.2% at 24 weeks. Those are not modest numbers. The Phase 2b IMPACT trial in 212 biopsy-confirmed MASH patients with F2-F3 fibrosis is the bigger story: 59.1% MASH resolution without fibrosis worsening at 1.2 mg versus 19.1% for placebo (p less than 0.0001). For context, resmetirom’s MASH approval was built on roughly 26% histological response rates. The FDA recognized the signal: Breakthrough Therapy Designation was granted in January 2026, alongside Fast Track for both MASH and AUD.

On the obesity side, the MOMENTUM trial showed 15.6% weight loss at 48 weeks, with 78.1% of that loss attributable to fat mass. Thats competitive with tirzepatide at comparable durations, though head-to-head data doesnt exist. The AUD indication is genuinely novel and the preclinical alcohol preference model is interesting, but human evidence there is still thin.

What we like: the GCGR-directed liver mechanism is real and well-differentiated from approved agents, the IMPACT biopsy data is exceptional for a Phase 2b readout, and BTD is a serious signal that the FDA considers the data compelling. What we don’t like: Phase 3 hasn’t run yet, Altimmune is a smaller shop operating in a space dominated by Novo Nordisk and Lilly, and survodutide plus other GLP-1/GCGR programs are actively competing. The evidence base is strong for its stage but not yet replicated across independent groups. For investigators studying MASH biology, incretin co-agonism, or liver-targeted metabolic pharmacology, this is one of the more interesting compounds in active clinical development right now.

Novelty

68

Mechanism promise

80

In-category differentiation

70

Evidence quality

62

Translational signal

77

Research bench value

60

Rationale Pemvidutide scores high on mechanism (deliberate 1:1 GLP-1R/GCGR co-agonism with liver-directed hepatic fat oxidation) and translational signal (59.1% biopsy-confirmed MASH resolution vs 19.1% placebo in the IMPACT Phase 2b, BTD granted January 2026). Pre-Phase 3 status, a competitive incretin landscape, and single-sponsor clinical data limit the ceiling on novelty and evidence scores.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Balanced dual glucagon-like peptide-1 (GLP-1) and glucagon receptor agonist peptide with glycolipid half-life extension

A 29-amino-acid unimolecular peptide engineered for equipotent GLP-1 and glucagon receptor co-agonism, conjugated to a proprietary glycolipid moiety for weekly subcutaneous dosing, under clinical development for metabolic dysfunction-associated steatohepatitis, obesity, and alcohol use disorder.

Abstract

Pemvidutide (ALT-801; CAS 2538014-94-5; UNII A35F525WBG; molecular formula C182H275N39O54; molecular weight 3873.42 g/mol) is a synthetic 29-amino-acid peptide that functions as a balanced (1:1) dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR), developed by Altimmune, Inc. (Gaithersburg, Maryland) for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), obesity, alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The compound incorporates sequence elements derived from both GLP-1 and glucagon and is conjugated to an 18-carbon diacid alkyl chain through a proprietary glycosidic linkage (designated EuPort), which provides near-quantitative but transient binding to serum albumin and extends the plasma half-life to a duration consistent with once-weekly subcutaneous administration without dose titration [1, 2]. The dual receptor mechanism differentiates pemvidutide from selective GLP-1 receptor agonists such as semaglutide and liraglutide: GLP-1R activation suppresses appetite through hypothalamic and brainstem satiety circuits, delays gastric emptying, and improves glycemic control, while GCGR activation directly stimulates hepatic fatty acid beta-oxidation, suppresses de novo lipogenesis, and increases energy expenditure through thermogenic pathways, producing a composite antisteatotic and weight-reducing pharmacology that is mechanistically suited to liver-predominant metabolic disease [3, 4, 5]. In the translational AMLN diet-induced obese mouse model of NASH, pemvidutide at 10 nmol/kg subcutaneous produced approximately 25 percent body weight reduction, significant reductions in liver triglycerides, galectin-3, collagen type 1 alpha 1, and NAFLD Activity Score, with efficacy exceeding that of semaglutide and elafibranor at equimolar doses on composite histological endpoints [6]. Clinical development has advanced through Phase 1 studies (NCT04561245, 100 subjects), Phase 1b/2a studies in MASLD (NCT05006885, 95 subjects; NCT05292911, 64 subjects), the Phase 2 MOMENTUM obesity trial (391 subjects, 48 weeks), and the Phase 2b IMPACT trial in biopsy-confirmed MASH (NCT05989711, 212 subjects) [1, 7, 8, 9, 10]. In the Phase 1b/2a MASLD study (Harrison et al. 2025), 12 weeks of pemvidutide at 1.8 mg weekly produced a 68.5 percent relative reduction in liver fat content by MRI-proton density fat fraction versus 4.4 percent for placebo (p < 0.001), with 55.6 percent of treated subjects achieving liver fat normalization to 5 percent or below [8]. Extension to 24 weeks produced 75.2 percent liver fat reduction at 1.8 mg and 6.2 percent body weight reduction versus placebo [7]. In the MOMENTUM trial, pemvidutide at 2.4 mg weekly for 48 weeks produced mean weight loss of 15.6 percent versus 2.2 percent on placebo, with body composition analysis demonstrating 78.1 percent of weight loss attributable to fat mass and 21.9 percent to lean mass [9, 10]. In the Phase 2b IMPACT trial (Noureddin et al. 2025) in 212 patients with biopsy-confirmed MASH and fibrosis stages F2 or F3, pemvidutide met the primary endpoint of MASH resolution without fibrosis worsening: 59.1 percent at 1.2 mg and 52.1 percent at 1.8 mg versus 19.1 percent for placebo (p < 0.0001 for both comparisons) [11]. Topline 48-week data demonstrated continued antifibrotic activity with statistically significant improvements in Enhanced Liver Fibrosis score and liver stiffness measurement versus placebo [12]. The United States Food and Drug Administration has granted Breakthrough Therapy Designation for pemvidutide in MASH (January 2026) and Fast Track designations for both MASH and AUD [13, 14]. Phase 3 registrational programs for MASH and the VELOCITY Phase 3 program for obesity are in planning as of May 2026. Safety across completed trials has been favorable; adverse events are predominantly gastrointestinal (nausea, diarrhea, decreased appetite), mild to moderate in severity, and concentrated in the first 16 weeks of treatment. No imbalances in cardiac events, arrhythmias, or clinically meaningful heart rate increases have been observed. This monograph reviews the compound identification, structural pharmacology, mechanism of action, pharmacokinetics, preclinical and clinical evidence base, sourcing and quality verification, reconstitution and handling, stack interactions, adverse events, and a comparative assessment of five alternative agents (survodutide, semaglutide, tirzepatide, cotadutide, resmetirom) against pemvidutide on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1410Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 10, 2026
Nitrous Oxide

Plain-language summaryIntrigue 70 / 100

Nitrous oxide is the oldest anesthetic gas in continuous clinical use, introduced by Horace Wells in 1844 for dental analgesia. Its MAC is 104 percent, meaning it cannot produce surgical anesthesia at atmospheric pressure when given alone (you would run out of inspired oxygen first). It is used as a co-administered agent with halogenated volatiles or IV induction agents to achieve additive anesthetic depth at safe oxygen levels. Mechanism is unusual for the class: principal action is NMDA antagonism (similar to ketamine and xenon) plus modest mu-opioid agonism contributing to analgesia, plus some GABA-A modulation. Pneumothorax expansion, middle ear pressure rise, and methionine synthase inhibition (B12 oxidation) are the main risks. Heavy non-medical use of food-grade cartridges has driven a recent epidemic of subacute spinal cord degeneration. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

34/100

A 180-year-old clinical workhorse with no compelling bench-scale research angle in 2026

Look, there’s something almost poetic about nitrous oxide appearing in the Kodiac library. 180 years of continuous clinical use, a mechanism that touches NMDA, opioid, and GABA-A pathways, and a pharmacokinetic profile that remains genuinely elegant (blood-gas partition coefficient of 0.47 means it’s in and out before most agents have reached steady state). We get the appeal. It’s historically significant and mechanistically interesting on paper.

Here’s the thing though: the research conversation around N2O moved on a long time ago. Its NMDA antagonism is real but low-potency, and the MAC exceeds 100 percent at atmospheric pressure, which means you can’t achieve surgical anesthesia with it alone without hitting hypoxia first. If you want to probe NMDA receptor pharmacology at the bench, ketamine is doing the heavy lifting. It’s selective, titratable, and the literature around ketamine/NMDA biology is orders of magnitude richer than anything N2O-specific. N2O is the compound that made ketamine’s NMDA story possible to recognize, but that recognition happened decades ago.

The evidence base is genuinely strong, we’ll give it that. FDA-approved, continuous clinical use, well-characterized pharmacokinetics, a clear mechanism for the vitamin B12 inhibition (cobalamin oxidation in methionine synthase). The Entonox literature for obstetric analgesia is solid. But strong evidence for a clinical tool doesn’t automatically translate to bench research value, and this is a research library.

What we dont like: the B12 issue isn’t just a clinical footnote. Repeated or prolonged exposure paradigms in any rodent or human study carry real confound risk via hyperhomocysteinemia and methionine synthase inhibition. That limits experimental design flexibility in a meaningful way. And practically, working with a compressed inhalational gas requires sealed delivery systems, special handling, and vapor concentration control that most bench labs aren’t configured for. The signal-to-hassle ratio is poor.

There’s also the differentiation problem. In every research-relevant context, a better probe exists. NMDA antagonism? Ketamine. Fast-onset/offset volatile anesthetic? Sevoflurane or desflurane. Anesthetic MAC additivity as a study design tool? The halogenated agents do it cleaner and with fewer confounds. N2O fills clinical gaps that have largely closed with modern practice.

Honestly, this compound belongs in an anesthesia history course or a clinical pharmacology reference shelf. As a live research target for a bench investigator building a serious program right now? It’s hard to make the case.

Novelty

8

Mechanism promise

22

In-category differentiation

18

Evidence quality

75

Translational signal

68

Research bench value

25

Rationale N2O scores low on novelty and differentiation because its NMDA mechanism, while real, is better probed by ketamine; strong evidence and translational scores reflect FDA-approved clinical use across two centuries, but those do not rescue bench research value for an investigator building a modern program.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Inorganic gaseous anesthetic and analgesic

The oldest anesthetic gas in continuous clinical use, an NMDA antagonist with low potency that supplements other agents and provides dental and obstetric analgesia.

Abstract

Nitrous oxide (N2O; dinitrogen monoxide; CAS 10024-97-2; molecular weight 44.01) is the oldest inhalational anesthetic agent in continuous clinical use, introduced by Horace Wells in 1844 for dental analgesia and by William Morton in operative anesthesia (in combination with ether) in the 1840s. The minimum alveolar concentration (MAC) is 104 percent at one atmosphere, indicating that nitrous oxide cannot produce surgical anesthesia at atmospheric pressure when administered alone (because hypoxia precedes anesthetic depth at concentrations approaching 100 percent inspired) and is used clinically as a co-administered agent with halogenated volatiles or intravenous induction agents to achieve MAC additivity at safe inspired oxygen fractions. Mechanism differs from the halogenated ethers: the principal target is NMDA glutamate receptor antagonism (similar to ketamine and xenon), with secondary effects on opioid receptor function (modest mu-receptor agonism contributing to analgesia), GABA-A modulation, and two-pore domain potassium channel activation. Pharmacokinetics: the blood-gas partition coefficient is 0.47 (rapid uptake and elimination); recovery is fast. The principal clinical risks are pneumothorax expansion (nitrous diffuses into closed gas spaces faster than nitrogen escapes), middle ear pressure increase, hyperhomocysteinemia from oxidation of cobalamin (B12) cofactor in methionine synthase (clinically apparent with prolonged or repeated exposure), and postoperative nausea and vomiting at higher rates than with halogenated agents alone. Recreational and substance-use disorder concerns have grown with availability of food-grade nitrous oxide cartridges; chronic non-medical use produces subacute combined degeneration of the spinal cord through methionine synthase inhibition. Dental and obstetric analgesic use (Entonox, 50:50 N2O/O2 premix) remains widespread.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1307Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 10, 2026
TAK-653 (NBI-1065845)

Our opinion on this compoundNovel, promising

63/100

Non-desensitizing AMPA PAM with real Phase 2a TRD signal; mechanism is genuinely new but evidence base remains thin

TAK-653 sits at an interesting intersection: it’s trying to solve a real problem with ampakines that work without the receptor desensitization that made CX-516 and similar compounds impractical, while targeting one of the hardest indications in psychiatry. The non-desensitizing mechanism is the actual story here. Earlier AMPA positive allosteric modulators ran into a hard ceiling where receptor desensitization meant that to get meaningful potentiation you had to push doses that caused cognitive impairment and in some cases seizure risk. TAK-653’s design addresses this directly by slowing deactivation rather than blocking desensitization outright, producing synaptic potentiation only under physiological glutamate signaling rather than tonic activation. That’s a pharmacologically clean profile, and it’s not easy to engineer.

We like the Phase 1 BOLD imaging data. Dose-dependent cortical activation consistent with AMPA potentiation is exactly the kind of translational signal you want before committing to Phase 2; it tells you the compound is doing what you think it’s doing in a living brain. The 2023 Phase 2a data from Neurocrine is more nuanced: numerical separation from placebo on Hamilton Depression Rating Scale at week 4, maintained through week 8, is real, but “numerical separation” is not the same as a clean effect size. TRD populations are heterogeneous and placebo response is notoriously variable. One Phase 2a study is not enough to call this a win, and the published language is cautious for a reason.

The positioning relative to ketamine and esketamine is where things get genuinely interesting from a research standpoint. If TAK-653 produces rapid-onset antidepressant effects through AMPA potentiation rather than NMDA blockade, that opens up real questions about the relative contribution of glutamatergic plasticity versus NMDA antagonism to ketamine’s mechanism; a debate thats still unresolved. As a probe compound, it lets you dissociate those two pathways in a way you cant do cleanly with ketamine alone. That’s real bench utility that exists independent of whether the clinical program ultimately succeeds.

What we dont love: a single Phase 2a study, modest language around effect sizes, and no Phase 3 timeline announced as of this writing. The Takeda-to-Neurocrine out-licensing is ambiguous; it might mean Neurocrine saw genuine development value, or it might mean Takeda deprioritized the asset internally. Sourcing for research use is constrained by the compound’s developmental status, with no established commercial synthesis pathway for broad distribution, which limits practical accessibility for labs outside an industrial partnership.

Honest take: TAK-653 is a compound worth watching, not necessarily worth anchoring a program to yet. The mechanism is well-reasoned and pharmacologically differentiated from every AMPA modulator that came before it. The Phase 2a signal is real if modest. The bench utility for dissecting glutamatergic contributions to depression biology is genuinely high. But one Phase 2a study and a licensing handoff doesnt make a proven platform, and the evidence base is still thin enough that serious investigators should treat this as a promising lead rather than an established tool.

Novelty

68

Mechanism promise

75

In-category differentiation

65

Evidence quality

48

Translational signal

50

Research bench value

63

Rationale The non-desensitizing allosteric AMPA potentiation mechanism is a meaningful pharmacological advance over earlier ampakines, and the 2023 Phase 2a data is real; scored down by single-study evidence base, modest effect-size language, no Phase 3 commitment, and developmental-stage sourcing constraints.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Non-desensitizing AMPA receptor positive allosteric modulator

A low-impairment AMPA receptor potentiator advanced through Phase 2 in treatment-resistant depression by Takeda and Neurocrine, distinguished from earlier ampakines by minimal receptor desensitization.

Abstract

TAK-653 (also designated NBI-1065845; emraclidine has the same NBI prefix, distinct compound; CAS 1626387-80-1; molecular formula C19H21F3N4O3S; molecular weight 442.46) is a small-molecule non-desensitizing positive allosteric modulator of AMPA-class glutamate receptors developed by Takeda and out-licensed to Neurocrine Biosciences for clinical development in treatment-resistant depression. The compound was selected from a structural class designed to achieve allosteric AMPA potentiation without the receptor desensitization characteristic of earlier ampakines (CX-516, CX-546), which limited potency and produced cognitive impairment at higher doses. TAK-653 binds at an allosteric site distinct from the glutamate-binding domain, slowing AMPA receptor deactivation and increasing the integrated current produced by physiological glutamate transients without persistent receptor activation in the absence of glutamate; this profile produces synaptic potentiation under physiological signaling without the off-target excitotoxicity concerns of full agonists or strongly desensitizing modulators. Phase 1 imaging studies report dose-dependent BOLD signal modulation in cortical regions consistent with AMPA potentiation. The compound was advanced through Phase 2 in treatment-resistant depression by Neurocrine; published Phase 2a results from 2023 reported numerical separation from placebo on Hamilton Depression Rating Scale change at week 4 with improvement maintained through week 8, with a favorable safety profile (no seizures, no notable sedation, no dose-limiting cognitive impairment). The compound has not yet received regulatory approval as of the most recent monograph revision. Distinguishing features versus other AMPA modulators are the absence of receptor desensitization, the minimal impairment profile at antidepressant doses, and the rapid-onset depression treatment positioning targeting the same therapeutic niche as ketamine and esketamine.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1327Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 10, 2026
Tesofensine

Our opinion on this compoundEstablished, active research

51/100

Triple reuptake inhibitor with a real Phase 2 weight-loss signal, now most interesting for hypothalamic obesity research

Tesofensine has one of the more interesting origin stories in obesity pharmacology: it failed in Alzheimer’s and Parkinson’s trials, and the weight loss that showed up as an adverse event became the entire rationale for repurposing. The 2008 Phase 2 published by Astrup et al. (roughly 160 patients, 24 weeks) showed approximately 10 percent body weight reduction at 0.5 mg/day, which was genuinely impressive at the time and outpaced liraglutide at standard doses by a real margin. That signal hasn’t been retracted. The problem is that the GLP-1 and dual-incretin era has since moved the goalposts considerably, and tesofensine’s headline number looks modest against semaglutide’s 15 percent and tirzepatide’s 20-plus. What was competitive in 2008 is a different conversation in 2025.

Mechanistically, balanced inhibition across all three monoamine transporters, DA, NE, and 5-HT, with similar affinity at each site hits mesolimbic reward circuits, prefrontal satiety signaling, and hypothalamic energy expenditure pathways simultaneously. That’s not a novel mechanism class. Cocaine covers this space nonselectively, sibutramine handled two of the three legs before withdrawal, and the basic pharmacology is well-characterized. What is distinctive is the 9-day plasma half-life, which creates a steady-state profile unlike anything else in the class and is genuinely useful for chronic exposure modeling in preclinical work. That kinetic fingerprint matters if you’re designing studies around sustained central monoamine elevation.

Here’s what actually makes tesofensine worth attention for a bench investigator right now: it’s not the general obesity indication. Saniona has pivoted the development program toward hypothalamic obesity, specifically Prader-Willi syndrome and craniopharyngioma-acquired hypothalamic obesity. These are populations where the normal satiety architecture is damaged or absent, which means the GLP-1 mechanism, dependent at least partly on intact hypothalamic GLP-1R signaling and downstream circuits, may not perform as expected. A central monoamine approach that compensates for broken hypothalamic regulation rather than trying to activate it is a mechanistically distinct rationale. Small populations, yes, but thats exactly the kind of clean indication-mechanism fit that produces interpretable research questions.

What we don’t love is the Phase 3 history. Enrollment paused multiple times owing to modest cardiovascular signals, blood pressure elevation, dry mouth, insomnia, and mood changes. That safety ceiling has capped tolerable dosing in ways that limit efficacy headroom. The compound isn’t scheduled in most jurisdictions, which keeps it accessible for research, but it’s also not approved anywhere, so the evidence base stops at Phase 2 with a stalled Phase 3. Evidence quality is real but thin at the top end.

We rate tesofensine established-active rather than novel-frontier. The repurposing story is nearly two decades old, the mechanism is a known class, and the incretin wave has redefined what competitive means in metabolic pharmacology. The hypothalamic obesity angle and the monoamine probe utility for energy homeostasis research keep this above mid-range, but serious investigators should go in with clear eyes about what Phase 3 stalls mean for translational confidence.

Novelty

42

Mechanism promise

60

In-category differentiation

52

Evidence quality

48

Translational signal

55

Research bench value

48

Rationale The mechanism is a known class, the 2008 Phase 2 is real but 17 years old, and the GLP-1 era has moved the goalposts on general obesity efficacy; scores mid-range because the hypothalamic obesity niche and monoamine probe utility are genuine research angles, but Phase 3 stalled and differentiation against current obesity pharmacology is limited.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Triple monoamine reuptake inhibitor (DA, NE, 5-HT)

A triple reuptake inhibitor originally developed for Alzheimer’s and Parkinson’s disease and repurposed for obesity, advanced through Phase 2 with substantial body weight reduction relative to placebo.

Abstract

Tesofensine (NS2330; CAS 195875-84-4; molecular formula C17H23Cl2N; molecular weight 312.28) is a triple monoamine reuptake inhibitor developed by NeuroSearch in the 1990s as a candidate for Alzheimer’s disease and Parkinson’s disease (where dopamine reuptake inhibition was hypothesized to provide motor symptom relief without the on-off fluctuations of L-DOPA). The compound failed to demonstrate efficacy in the original Alzheimer’s and Parkinson’s indications; weight loss observed as an adverse event in the central nervous system trials motivated repurposing for obesity, with Phase 2 data published in 2008 showing approximately 10 percent body weight reduction at 24 weeks at the 0.5 mg dose, substantially greater than the comparator orlistat and meaningfully greater than the GLP-1 agonist liraglutide at typical doses. Mechanism is competitive inhibition at the dopamine, norepinephrine, and serotonin transporters with similar affinity at all three sites; the integrated effect is monoamine elevation in mesolimbic, prefrontal, and hypothalamic targets that suppresses appetite and increases energy expenditure. The compound was advanced through Phase 3 by NeuroSearch and partner Saniona for obesity but Phase 3 enrollment was paused multiple times owing to safety signals (modest blood pressure elevation, dry mouth, insomnia, mood changes) and the program has progressed slowly relative to the more recent GLP-1 class. Saniona has continued development for hypothalamic obesity (Prader-Willi syndrome and acquired hypothalamic obesity from craniopharyngioma surgery), with the rationale that the central monoamine elevation may compensate for hypothalamic dysfunction in these niche populations. The compound is not approved in any jurisdiction. Plasma half-life is approximately 9 days, suitable for once-daily oral administration with steady-state achieved over 4 weeks.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1341Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 10, 2026
PHA-543613

Our opinion on this compoundNiche research probe

52/100

Premier selective alpha-7 full agonist tool compound with strong bench utility but no human data and a class history of clinical failure

Look, the alpha-7 nicotinic field has one of the longer lists of clinical disappointments in CNS pharmacology. GTS-21 stalled in development. Encenicline failed Phase 2 trials in both schizophrenia and Alzheimer disease and Pfizer shelved it. The promise of selective nicotinic receptor pharmacology in cognitive disease has been held out for thirty years without a clean win in humans. So why is PHA-543613 worth discussing? Because it isn’t a clinical candidate. It’s a tool, and on that specific dimension it’s the best one available.

The distinguishing feature is full agonism paired with genuine subtype selectivity. Most alpha-7 compounds in active research use are partial agonists: tropisetron sits at roughly 25 to 40 percent intrinsic activity at alpha-7, GTS-21 at 30 to 50 percent, encenicline at 60 to 70 percent. PHA-543613 comes in at 80 to 90 percent of the acetylcholine maximum across Xenopus oocyte and heterologous cell-line expression systems. That matters when the research question is what happens under near-maximal alpha-7 engagement. Partial agonists contaminate the readout at the ceiling. The roughly 100-fold selectivity window over alpha-4-beta-2 and alpha-3-beta-4 subtypes means youre not running an inadvertent parallel experiment on the rest of the nAChR family whenever you attribute an effect to alpha-7.

The recent preclinical record is substantive and methodologically credible. Hijazi et al. (2023) used the presenilin 1 and presenilin 2 conditional double-knockout mouse, which is among the more mechanistically faithful familial AD models in current use, and showed meaningful cognitive rescue with PHA-543613. The combination pharmacology work is what we find most interesting: aged-rat studies pairing PHA-543613 with memantine at doses that extrapolate plausibly to clinically available memantine exposures demonstrate synergy that neither compound produces as monotherapy. The biological rationale is coherent: alpha-7-mediated calcium influx and downstream PI3K/Akt signaling running in parallel with NMDA receptor antagonism targeting a distinct synaptic calcium-handling mechanism. Thats a genuinely testable combination hypothesis with real translational scaffolding.

We don’t love the translational picture, honestly. No human data, not Phase 1, not even formal IND-enabling studies on record. The rodent cognitive models anchoring PHA-543613’s preclinical case, scopolamine-induced impairment, MK-801 blockade, amyloid fragment infusion, are the same models that predicted clinical success for encenicline and several other alpha-7 compounds. Those predictions did not hold. That track record has to weigh on how much you trust bench-to-clinic extrapolation in this receptor class specifically.

What pushes the bench value score up is exactly what you’d expect from a well-characterized tool compound. If youre doing alpha-7 nAChR receptor biology, combination cholinergic pharmacology, or AD mechanistic work in rodent models, this compound is difficult to replace. No other widely available molecule gives you selective full agonism with a brain-to-plasma ratio of five to ten in rodents, confirmed oral bioavailability, and two decades of published dose-response literature to anchor new studies against. For investigators running AD combination pharmacology programs or neurotransmitter systems research, PHA-543613 earns a serious toolkit position. For anyone looking for a clinical development candidate in the alpha-7 class, bradanicline and the newer quinuclidine-benzofuran series are the more plausible targets.

Novelty

42

Mechanism promise

58

In-category differentiation

72

Evidence quality

40

Translational signal

30

Research bench value

74

Rationale PHA-543613 scores highest on differentiation and bench value: it is the definitive selective alpha-7 nAChR full agonist tool compound, essentially irreplaceable for investigators who need saturating, selective alpha-7 engagement uncomplicated by partial-agonist ceiling effects or nAChR subtype bleed-through. Translational signal is low given zero human trials and the alpha-7 class’s string of clinical failures; mechanism is solid but not novel by current standards. Overall 52 reflects an indispensable probe for a specific, relatively narrow research niche.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective alpha-7 nicotinic acetylcholine receptor full agonist (preclinical research compound)

A quinuclidine furo[2,3-c]pyridine-5-carboxamide developed at Pfizer in the mid-2000s as a brain-penetrant, orally bioavailable selective alpha-7 nicotinic full agonist with substantial preclinical pharmacology in rodent cognitive models. The principal high-potency selective alpha-7 nicotinic agonist in current research use as a tool compound, with no advancement to human clinical trials but extensive use in fundamental and combination-pharmacology studies including the recent presenilin double-knockout mouse model of Alzheimer disease and synergistic combination work with memantine in aged rats.

Abstract

PHA-543613 is a small-molecule, brain-penetrant, orally bioavailable selective full agonist of the homopentameric alpha-7 subtype of the neuronal nicotinic acetylcholine receptor, originated at Pfizer Global Research and Development in the mid-2000s as part of an alpha-7 nicotinic receptor medicinal-chemistry program for cognitive enhancement applications. The compound is a quinuclidine furo[2,3-c]pyridine-5-carboxamide, structurally related to the quinuclidine-amide alpha-7 family that includes encenicline (a quinuclidine benzothiophene-2-carboxamide) and bradanicline (a quinuclidine benzofuran-2-carboxamide), distinguished by the fused furo[2,3-c]pyridine bicyclic system in the amide-bearing aryl group. The chemistry was disclosed in the seminal Wishka et al. (2006) Journal of Medicinal Chemistry report from Pfizer, which described the structure-activity relationship study, the optimization to PHA-543613 as the lead compound, and the preliminary pharmacology supporting brain penetration, oral bioavailability, and alpha-7 selectivity [1]. The compound has not been advanced to human clinical trials; the published pharmacology is principally preclinical (rodent species). PHA-543613 binds the human alpha-7 nicotinic receptor at the orthosteric (acetylcholine) site with low-nanomolar affinity (Ki approximately 8 nanomolar at human alpha-7 expressed in heterologous systems) and acts as a full agonist with intrinsic functional activity of approximately 80 to 90 percent of the acetylcholine maximum response in Xenopus oocyte and cell-line expression systems, comparable to bradanicline and substantially higher than encenicline (60 to 70 percent), tropisetron (25 to 40 percent), and GTS-21 (30 to 50 percent). Selectivity over other neuronal nicotinic subtypes (alpha-4-beta-2, alpha-3-beta-4) is approximately 100-fold or greater. The compound exhibits good oral bioavailability and high brain penetration in rodent species (brain-to-plasma ratio approximately 5 to 10), supporting central nervous system pharmacology at oral doses of 0.3 to 10 milligrams per kilogram. The principal published pharmacology comprises rodent behavioral studies in scopolamine-induced cognitive impairment, MK-801-induced cognitive impairment, beta-amyloid-induced cognitive deficit (the Aβ25-35 mouse model), aged-rat working memory paradigms, and the recent Hijazi et al. (2023) presenilin 1 and presenilin 2 conditional double knockout mouse model of familial Alzheimer disease [2, 3, 4]. The compound has demonstrated reversal of cognitive deficits across these models with effect sizes substantially exceeding the alpha-7 partial agonists tested in parallel comparisons (notably exceeding galantamine in head-to-head comparisons in the aged-rat model). Substantial recent work has characterized the synergistic combination of PHA-543613 with memantine (an NMDA receptor antagonist, the FDA-approved Alzheimer disease drug) in aged rats, with the combination demonstrating greater cognitive benefit than either compound as monotherapy at clinically translatable doses [4]. The combination work supports a contemporary research-clinical hypothesis that combination pharmacology of alpha-7 nicotinic full agonism (PHA-543613-class) with NMDA receptor antagonism (memantine) and acetylcholinesterase inhibition (donepezil-class) may produce cognitive benefits exceeding those achievable with monotherapy in any single mechanism class. PHA-543613 has not been licensed to a clinical-development entity for human trials as of the most recent monograph revision; the compound therefore serves as a research tool rather than as a clinical candidate. Research-grade PHA-543613 is widely available from chemical suppliers at moderate cost and is one of the most extensively used alpha-7 nicotinic receptor agonist tool compounds in contemporary fundamental pharmacology research. This monograph reviews the chemistry, synthesis, and stereochemistry of PHA-543613; the receptor pharmacology in molecular and electrophysiological detail; the preclinical pharmacokinetic record in rodent species; the comprehensive preclinical pharmacology across cognitive enhancement, neuroprotection, and combination pharmacology applications; sourcing, reconstitution, and stack-interaction considerations; the safety record (preclinical only); and a structured comparative assessment of five alpha-7 nicotinic acetylcholine receptor candidates against PHA-543613 on the five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1356Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 10, 2026
Dapiglutide

Our opinion on this compoundNovel, promising

60/100

First-in-class dual GLP-1R/GLP-2R agonist with a real gut barrier angle, paused before Phase 3 in a brutal competitive field

Look, dapiglutide is doing something genuinely different in the incretin space. While the rest of the field was stacking GIP onto GLP-1 (tirzepatide) or adding glucagon (survodutide, retatrutide), Zealand Pharma took the GLP-2 receptor seriously as an obesity target. The rationale isnt crazy: GLP-2R activation promotes intestinal epithelial proliferation, tightens paracellular tight junctions through claudin-7 upregulation, and suppresses mucosal inflammation in the gut. If obesity-associated low-grade inflammation is partly a gut barrier story, thats a real hypothesis worth testing in a molecule and one that no approved incretin currently addresses head-on.

The biased agonism piece adds a second layer of mechanistic interest. Dapiglutide acts as a full cAMP agonist at the GLP-1R while producing markedly blunted beta-arrestin recruitment relative to native GLP-1. In vitro, that profile extends cAMP production to roughly 12 hours. Whether signaling bias translates to a clinically meaningful reduction in receptor desensitization is still an open question, but as a probe for studying GLP-1R internalization dynamics, the compound occupies a niche that semaglutide and tirzepatide dont fill the same way.

The clinical data tell a mixed story, honestly. The Phase 1b 28-week extension is the headline number: 11.6 percent mean body weight reduction versus 0.2 percent on placebo. Thats a real signal. But the DREAM trial, a more deliberately designed Phase 2a proof-of-concept in 54 participants with obesity, evaluated lower doses and missed its primary endpoint; HbA1c reduction at 6 mg was statistically significant, the weight reduction was not. All of it comes from a single sponsor with no independent replication, and the trials are small. Thirty participants in the pivotal arm is a thin thread to hang a mechanism story on.

Then came the 2025 program pause. Zealand cited portfolio prioritization, which is the corporate translation of we cant compete with retatrutide and next-generation oral GLP-1s on weight loss numbers alone. That is a completely legitimate commercial read, and it means no Phase 3 data is coming. That caps how far anyone can push the translational argument in good conscience.

What we think is genuinely interesting here: the dual-receptor angle on the obesity-inflammation-gut barrier intersection is real science, the biased agonism profile is a useful research tool, and the preclinical intestinal barrier data in short bowel syndrome models is methodologically solid. For investigators studying incretin receptor pharmacology, class B GPCR signaling bias, or gut epithelial function in metabolic disease, dapiglutide sits in a niche that no approved compound fills. What we dont like is the thin and unconfirmed evidence base, the absence of any independent replication, and an effect size that couldn’t survive a competitive development environment. The score reflects a compound with genuine mechanistic novelty and modest but real human signal, held back by early-stage data and a program now formally on ice.

Novelty

68

Mechanism promise

74

In-category differentiation

58

Evidence quality

40

Translational signal

50

Research bench value

60

Rationale Dapiglutide’s dual GLP-1R/GLP-2R mechanism and biased-agonism profile are genuinely novel in the incretin class, scoring well on novelty and mechanism, but single-sponsor Phase 1/2a data, a missed DREAM primary endpoint, and the 2025 program pause all drag evidence and translational scores down to realistic levels.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Dual GLP-1/GLP-2 receptor agonist peptide with biased signaling and prolonged pharmacokinetics

A first-in-class 33-amino-acid acylated peptide dual agonist of the glucagon-like peptide 1 and glucagon-like peptide 2 receptors developed by Zealand Pharma for the treatment of obesity and obesity-associated low-grade inflammation, distinguished from conventional incretin-class therapeutics by the addition of GLP-2-receptor-mediated intestinal barrier repair and anti-inflammatory activity to GLP-1-receptor-mediated anorectic and glucometabolic effects.

Abstract

Dapiglutide (ZP 7570; CAS 2296814-85-0; molecular formula C192H302N46O57; molecular weight 4166.79 g/mol) is a synthetic 33-amino-acid peptide dual agonist of the human glucagon-like peptide 1 receptor (GLP-1R) and glucagon-like peptide 2 receptor (GLP-2R) bearing a C18 fatty acid acyl modification that extends plasma half-life to approximately 123 to 129 hours and permits once-weekly subcutaneous administration [1, 2]. Developed by Zealand Pharma A/S (Copenhagen, Denmark) as a potential first-in-class agent for obesity and its inflammatory comorbidities, dapiglutide was designed to exploit the complementary pharmacology of the two incretin receptors: GLP-1R activation suppresses appetite, delays gastric emptying, and improves glucose homeostasis through cyclic adenosine monophosphate (cAMP)-dependent signaling in pancreatic beta cells, hypothalamic appetite circuits, and vagal afferents; GLP-2R activation promotes intestinal epithelial proliferation, enhances paracellular tight junction integrity, and suppresses mucosal inflammation through cAMP-dependent signaling in enteroendocrine cells, subepithelial myofibroblasts, and enteric neurons [3, 4]. At the molecular level, dapiglutide exhibits biased agonism at the GLP-1R, displaying full agonist activity for cAMP formation while producing significantly blunted beta-arrestin recruitment, a signaling profile associated with reduced receptor desensitization and sustained intracellular cAMP production for up to 12 hours in vitro [5]. The compound entered clinical development in 2020 with a Phase 1 single-ascending-dose and multiple-ascending-dose trial in healthy volunteers demonstrating dose-proportional pharmacokinetics, a favorable safety profile dominated by mild gastrointestinal adverse events, and dose-dependent body weight reductions of up to 4.3 percent from baseline after four weeks of once-weekly dosing [1, 2]. A subsequent 13-week Phase 1b multiple-ascending-dose extension in 54 participants with overweight or obesity (BMI 27 to 40 kg/m2) reported placebo-adjusted body weight reductions of up to 8.3 percent, with no severe treatment-emergent adverse events [6]. A 28-week extension of the same trial (Part 2, 30 participants, doses up to 26 mg weekly) reported mean body weight reduction of 11.6 percent versus 0.2 percent on placebo, with continued favorable tolerability [7]. An investigator-led mechanistic trial (DREAM; 54 participants with obesity, BMI greater than or equal to 30 kg/m2) evaluated lower doses (4 mg and 6 mg) over 12 weeks and reported body weight reductions of 2.9 and 4.3 percent respectively versus 2.2 percent on placebo; the primary endpoint did not achieve statistical significance, though HbA1c reduction was significant at 6 mg [8, 9]. The preclinical pharmacology of dapiglutide includes demonstration of intestinal barrier repair in murine short bowel syndrome models, where the compound promoted claudin-7 expression, tightened the paracellular leak pathway, improved oral glucose tolerance, reduced intestinal transit time, increased villus height and intestinal length, and reduced stool water losses [10, 11]. Zealand Pharma paused the dapiglutide program in 2025, citing portfolio prioritization in an increasingly competitive metabolic disease landscape, though the Phase 1b 28-week data were subsequently reported as positive [7, 12]. The compound is not approved in any jurisdiction. It is available from select research chemical suppliers for investigational use only.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1413Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 10, 2026
Lotiglipron

Our opinion on this compoundNiche research probe

48/100

Discontinued oral small-molecule GLP-1R agonist with real Phase 2 data and a program-ending hepatic liability

Look, lotiglipron is one of those compounds that’s worth understanding, but not because you’d anchor a research program around it today. Pfizer’s PF-07081532 was a serious attempt at oral small-molecule GLP-1R agonism using Sosei Heptares StaR technology, which gave the design team crystallographic access to the receptor’s transmembrane domain in a conformation stable enough for real structure-based work. That’s not a trivial achievement. The binding mode is transmembrane rather than extracellular, unlike peptide GLP-1R agonists, and that pharmacological distinction is genuinely worth caring about if you’re trying to understand functional selectivity and signaling bias at GLP-1R.

Phase 2 confirmed what the mechanism predicted: glucose lowering and a weight reduction signal in both T2D and obesity cohorts. The PK was actually attractive, a half-life of 21 to 27 hours with once-daily dosing and no fasting requirement, which would have been a competitive advantage in the oral incretin space. But the program ended in 2023 when hepatic transaminase elevations appeared in a subset of participants at sufficient frequency to close the Pfizer filing. That fact now organizes almost everything scientifically interesting about lotiglipron. The efficacy is predictable from the mechanism and not especially notable. The hepatotoxicity is the open question.

Thats where the bench value sits right now. If you’re working on the oral nonpeptide GLP-1R agonist class, you need to understand the hepatic liability profile, and lotiglipron is one of the two major clinical data points (danuglipron being the other, also Pfizer, also discontinued in the same period) that define the problem. Orforglipron from Lilly is the surviving frontrunner and appears to be clearing the hepatic hurdle that lotiglipron did not. Understanding why is a legitimate, unresolved mechanistic question with real clinical implications for the whole class.

The differentiation picture is genuinely poor. Orforglipron has a better safety trajectory, Phase 3 enrollment underway, and owns the class from a development standpoint. Lotiglipron’s interest is comparative and structural, not competitive. For investigators studying GPCR transmembrane domain pharmacology, the compound comes with a clinical dataset attached, which is unusual and useful. For anyone wanting to run a GLP-1R agonism program, its not the starting point.

We also dont love the evidence situation. The Phase 2 data is real and multi-site, but the program was terminated before replication could accumulate. The hepatic signal is documented but the underlying mechanism, whether it’s metabolite-mediated, target-related, or idiosyncratic, remains unresolved. Useful for comparison. Not compelling as a primary object of investigation unless hepatic liability in small-molecule GPCR agonists is your specific question.

Novelty

60

Mechanism promise

58

In-category differentiation

28

Evidence quality

50

Translational signal

40

Research bench value

50

Rationale Lotiglipron sits in an unusual position: a genuinely novel-class compound discontinued for safety rather than efficacy failure, giving it residual research value as a comparative probe for hepatotoxicity in oral small-molecule GLP-1R agonists. Differentiation scores low because orforglipron has a stronger safety trajectory and defines the class; lotiglipron’s primary scientific interest is now forensic rather than developmental.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Oral nonpeptide small-molecule glucagon-like peptide-1 receptor agonist

A selective, potent, orally bioavailable small-molecule agonist of the human glucagon-like peptide-1 receptor developed by Pfizer using Sosei Heptares stabilized-receptor technology, advanced through Phase 2 for type 2 diabetes and obesity, and subsequently discontinued owing to hepatic transaminase elevations in a subset of treated participants.

Abstract

Lotiglipron (PF-07081532) is an orally administered, nonpeptide, small-molecule agonist of the human glucagon-like peptide-1 receptor (GLP-1R) developed by Pfizer in collaboration with Sosei Heptares. The compound was designed through structure-based drug design leveraging Sosei Heptares proprietary StaR (stabilized receptor) technology platform, which enables crystallographic resolution of G-protein-coupled receptor conformations that are otherwise too unstable for conventional structural characterization. Lotiglipron binds within the transmembrane domain of the GLP-1R, activating the Gs-coupled adenylyl cyclase signaling cascade and increasing intracellular cyclic adenosine monophosphate (cAMP) in a manner functionally analogous to the endogenous incretin peptide GLP-1(7-36)amide but with the pharmacokinetic advantages of oral bioavailability, once-daily dosing without fasting requirements, and a plasma elimination half-life of approximately 21 to 27 hours that supports sustained receptor engagement across the dosing interval.

The compound entered clinical development in 2021 and was advanced through two Phase 1 multiple-ascending-dose studies (Buckeridge et al. 2024) in 74 participants with type 2 diabetes mellitus (T2D) and 26 participants with obesity without diabetes, demonstrating dose-proportional pharmacokinetics across a 10 to 180 mg once-daily dose range, dose-dependent reductions in glycated hemoglobin (HbA1c) of up to 1.61 percentage points at the 180 mg dose over 42 days, and a safety and tolerability profile consistent with the GLP-1R agonist mechanism class. These findings supported advancement to a Phase 2 dose-ranging study (Amin et al. 2025) in 901 participants (512 with T2D, 389 with obesity), which demonstrated statistically significant reductions in HbA1c of up to 1.44 percentage points (80 mg dose, 16 weeks) and body weight reductions of up to 7.47 percent (200 mg dose, 20 weeks). The Phase 2 study included an open-label semaglutide 14 mg comparator arm; lotiglipron at doses above 20 mg produced HbA1c reductions numerically comparable to or exceeding semaglutide at week 16. However, the Phase 2 study was terminated early following identification of hepatic transaminase elevations (alanine aminotransferase and/or aspartate aminotransferase greater than 3 times the upper limit of normal) in 6.0 to 6.6 percent of lotiglipron-treated participants versus 1.6 percent on placebo, with some individuals reaching elevations greater than 8 times the upper limit of normal. No cases of liver failure, symptomatic hepatitis, or Hy’s law were reported. In June 2023, Pfizer announced discontinuation of the lotiglipron clinical program based on the transaminase signal, pharmacokinetic data from Phase 1 drug-drug-interaction studies suggesting impaired hepatic drug transport or metabolism in a subset of participants, and the inability to prospectively identify at-risk individuals.

Lotiglipron is structurally characterized as a benzimidazole-piperidinyl-benzodioxole derivative bearing a chloropyridinyl substituent and an oxetanylmethyl group (molecular formula C31H31ClN4O5, molecular weight 575.05 g/mol as free base; CAS 2401892-75-7). The compound is not approved in any jurisdiction and is not in active clinical development. Research-grade lotiglipron is available from multiple chemical suppliers and remains a tool compound for the investigation of small-molecule GLP-1R agonist pharmacology, biased signaling, and hepatic metabolism of the oral GLP-1R agonist class. This monograph reviews the chemistry, synthesis, receptor pharmacology, pharmacokinetics, preclinical and clinical evidence, sourcing and handling, stack interactions, adverse events, and a comparative assessment against five oral or nonpeptide GLP-1R agonist candidates on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1409Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 10, 2026
Levobupivacaine

Plain-language summaryIntrigue 55 / 100

Levobupivacaine (Chirocaine) is the (S)-enantiomer of bupivacaine, separated out specifically to address the racemate’s cardiotoxicity. Approved by the FDA in 1999. Toxicology comparisons in rat and pig models show 30 to 40 percent lower toxic dose ratios for cardiovascular collapse and seizures than racemic bupivacaine at equivalent neural block efficacy, since the (R)-enantiomer carries most of the cardiac risk through tighter sodium channel binding and slower dissociation. Clinical equivalence trials in epidural, spinal, and peripheral nerve block showed non-inferior efficacy with cleaner CNS toxicity profiles in inadvertent intravascular dosing. Withdrawn from the US market in 2010 for commercial reasons but still available in Europe and Asia. Cost relative to racemic bupivacaine has limited adoption despite the safety advantage. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

34/100

Mature S-enantiomer local anesthetic with a solved safety problem and limited new research angles

Look, levobupivacaine is a solved problem. The question it answers, “can we keep long-acting neural blockade while reducing cardiac toxicity,” was answered in clinical practice by the late 1990s when Chiroscience pushed the S-enantiomer separation through regulatory review. The mechanism is pure voltage-gated sodium channel block, identical to racemic bupivacaine except the (R)-enantiomer’s tighter cardiac sodium channel affinity and slower off-rate is removed from the equation. Thats a real and meaningful safety improvement. It just isnt a research frontier anymore.

The enantioselective pharmacology story, that the (R)-enantiomer carries the dominant cardiotoxic burden through higher hNav1.5 affinity and slower kinetics, is well-documented across rat and pig LAST models and confirmed in inadvertent intravascular dosing case series. The 30 to 40 percent improvement in toxic-dose ratio is genuine. But the head-to-head comparison with ropivacaine, the other clinically available S-enantiomer amide that occupies the same safety-improved niche, is not flattering. Ropivacaine never left the US market. Levobupivacaine was withdrawn in 2010 for commercial reasons, which tells you a lot about where it sits in the competitive landscape even before you open a research question.

We don’t see a meaningful bench program that requires levobupivacaine specifically. If you’re probing stereoselective sodium channel pharmacology, you can use the racemate and pure enantiomers with well-established protocols. If you’re modeling LAST and lipid emulsion rescue, racemic bupivacaine is actually the preferred model compound precisely because it induces the severe toxicity you’re trying to reverse. If you’re comparing long-acting local anesthetics for regional anesthesia research, ropivacaine and liposomal bupivacaine formulations (Exparel-type) are the live clinical questions. Levobupivacaine sits awkwardly outside all three.

The evidence quality and translational scores are the only things keeping this above 30. It is an FDA-approved compound with replicated phase 3 equivalence data across epidural, spinal, and peripheral nerve block indications. The mechanism is precisely understood. Pharmacokinetics are well-characterized. For any investigator building a study around amide local anesthetic chiral pharmacology in a non-US jurisdiction where the compound is still sourced, it has real utility as a comparator. Honestly, thats a narrow lane. We’d reach for ropivacaine first in almost every scenario that isn’t specifically about the Chirocaine safety profile in a regional context.

What this compound represents, historically, is a smart piece of medicinal chemistry that arrived at roughly the right answer on cardiac safety and then got eclipsed by its competition. The underlying science is solid. The research opportunity in 2025 is not.

Novelty

20

Mechanism promise

20

In-category differentiation

25

Evidence quality

62

Translational signal

58

Research bench value

28

Rationale Levobupivacaine scores low on novelty and mechanism because it is purely a chiral refinement of a 1960s drug class with identical pharmacology; the enantioselectivity story was interesting in the late 1990s but the literature is fully settled. Evidence and translational scores pull the overall up modestly because this is an approved drug with replicated clinical data, but the US withdrawal and ropivacaine’s direct overlap cap differentiation and bench value.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Amide local anesthetic (S-enantiomer of bupivacaine)

The (S)-enantiomer of bupivacaine, marketed as Chirocaine, with a reduced cardiotoxic and CNS toxic profile relative to the racemate.

Abstract

Levobupivacaine ((S)-1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide; CAS 27262-47-1; molecular formula C18H28N2O; molecular weight 288.43) is the (S)-enantiomer of bupivacaine, developed by Chiroscience and Purdue and approved by the FDA in 1999 (Chirocaine). The enantioselective pharmacology of bupivacaine motivated separation: the (R)-enantiomer carries the dominant cardiotoxic and CNS toxic burden through higher cardiac sodium channel affinity and slower dissociation, while the (S)-enantiomer produces equivalent neural block with substantially reduced toxic margin. Direct toxicology comparisons in rat and pig models show 30 to 40 percent lower toxic dose ratios for cardiovascular collapse and seizure threshold with levobupivacaine versus racemic bupivacaine at equivalent neural block efficacy. Clinical equivalence trials in epidural, spinal, and peripheral nerve block applications demonstrate non-inferior efficacy with lower incidence of CNS toxicity in inadvertent intravascular dosing. Mechanism is identical to racemic bupivacaine (voltage-gated sodium channel block) with the favorable enantioselectivity at cardiac sodium channels driving the safety advantage. Onset, duration, and maximum recommended doses are similar to bupivacaine; some sources permit slightly higher cumulative levobupivacaine doses (3 mg/kg without epinephrine) reflecting the safety margin. The principal limitation of levobupivacaine is acquisition cost relative to racemic bupivacaine, which has restricted uptake in some markets despite the favorable safety profile. The compound was withdrawn from the US market in 2010 for commercial reasons but remains available in Europe and Asia. Lipid emulsion rescue is the standard therapy for any LAST event.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1310Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 10, 2026
Survodutide

Our opinion on this compoundNovel, promising

64/100

A dual GLP-1/glucagon agonist with real Phase 3 promise, strongest case in MASH

Look, survodutide is a serious compound in a seriously competitive space. Boehringer Ingelheim and Zealand Pharma built this as a 39-residue lipidated peptide with roughly balanced activity at both GLP-1 and glucagon receptors, and the pharmacokinetic strategy is exactly what you’d expect from this generation of metabolic peptides: a fatty acid chain for serum albumin binding, once-weekly subcutaneous dosing. Familiar architecture, but the glucagon receptor agonism is where the real story is.

Here’s the thing about adding glucagon to GLP-1: it’s not just additive appetite suppression. GLP-1 handles the central appetite and gastric emptying piece, but glucagon receptor agonism specifically drives hepatic fatty acid oxidation and increases whole-body energy expenditure in a way that GLP-1 monoagonists can’t replicate. That combination is what produced approximately 19 percent body weight reduction at 46 weeks in Phase 2 data published in 2024, numbers that land in tirzepatide territory and well ahead of semaglutide’s ceiling.

What we find genuinely compelling here is the MASH angle. Metabolic dysfunction-associated steatohepatitis is a brutal target: large unmet need, a liver disease that’s difficult to reverse, and the glucagon receptor mechanism drives hepatic fat mobilization directly. That’s mechanistically more targeted for MASH than pure GLP-1 agonism or even the GIP/GLP-1 combination in tirzepatide. The SYNCHRONIZE-2 trial is one of the more interesting things in the MASH pipeline right now, and a clean liver histology signal from that program would reposition survodutide decisively above every pure GLP-1 agent in the hepatic disease space.

The honest scoring issue for survodutide is differentiation in the obesity indication. Tirzepatide is approved and defines that category. Retatrutide adds GIP receptor agonism on top of the glucagon and GLP-1 already in survodutide’s profile, with a potentially higher efficacy ceiling. Survodutide doesnt have GIP, and if Lilly’s triple agonist survives Phase 3, that absence matters for the obesity claim. The GIP component in tirzepatide turned out to be important for insulin sensitization and weight loss ceiling; glucagon addresses energy expenditure and hepatic fat clearance but doesnt replicate the same glucose-handling angle.

That said, Phase 3 SYNCHRONIZE obesity data aren’t in yet, and the MASH program is genuinely differentiated from anything tirzepatide or semaglutide is positioned to do. Survodutide also clearly outclasses cotadutide on pharmacokinetic profile. We think this is a compound worth active tracking, especially heading into the 2026 to 2027 regulatory submission window. Strong Phase 2 human data, a coherent dual mechanism with a real hepatic rationale, and unmet-need positioning in MASH. It just isn’t the category-defining move that tirzepatide was when the GIP controversy was still live.

Novelty

60

Mechanism promise

70

In-category differentiation

65

Evidence quality

58

Translational signal

68

Research bench value

58

Rationale Solid Phase 2 human efficacy (~19% weight loss at 46 weeks) and a mechanistically coherent glucagon-driven MASH angle push scores up, but survodutide competes directly with tirzepatide in obesity and lacks GIP receptor agonism; pending Phase 3 readouts keep evidence and translational scores from reaching the high 70s.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

GLP-1 and glucagon receptor dual agonist

A long-acting GLP-1 and glucagon receptor dual agonist developed by Boehringer Ingelheim and Zealand Pharma, advanced through Phase 3 in obesity and MASH.

Abstract

Survodutide (BI 456906; SAR-441255; CAS 2403761-22-2 mass) is a long-acting GLP-1 receptor and glucagon receptor dual agonist developed by Boehringer Ingelheim in collaboration with Zealand Pharma. The compound is a 39-residue lipidated peptide based on the glucagon and GLP-1 sequences, with selective potency approximately equivalent at the two receptors and with a fatty acid chain modification enabling once-weekly subcutaneous administration through serum albumin binding (the same pharmacokinetic strategy used by semaglutide, liraglutide, and tirzepatide). The dual-agonist mechanism produces synergistic effects on body weight: GLP-1 receptor agonism reduces appetite and slows gastric emptying through hypothalamic and brainstem pathways (the dominant mechanism shared with semaglutide and other GLP-1 monoagonists), while glucagon receptor agonism increases hepatic fatty acid oxidation and energy expenditure, mobilizing hepatic and visceral fat in a manner not achieved by GLP-1 monoagonism. Phase 2 obesity results published in 2024 reported up to approximately 19 percent body weight reduction at 46 weeks at the highest dose, similar to the magnitude observed with tirzepatide and substantially greater than semaglutide. The compound is in active Phase 3 development in obesity (SYNCHRONIZE program) and MASH (SYNCHRONIZE-2; metabolic dysfunction-associated steatohepatitis) with anticipated regulatory submissions in 2026 to 2027. Side effect profile parallels other GLP-1-class agents (nausea, vomiting, diarrhea, occasional gastroparesis) with the additional consideration of glucagon-related effects (modest heart rate elevation, occasional hypoglycemia masked by reduced insulin sensitivity, and consideration of bilirubin elevation). Survodutide is distinct from retatrutide (Eli Lilly’s triple GLP-1/GIP/glucagon agonist) in lacking GIP receptor agonism and from cotadutide (AstraZeneca’s GLP-1/glucagon dual) in pharmacokinetic profile and clinical positioning.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1342Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 10, 2026

←Previous Page

1 … 25 26 27 28 29 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.